[
    [
        {
            "time": "2023-10-05",
            "original_text": "Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal",
            "features": {
                "keywords": [
                    "Lilly",
                    "Phase III",
                    "Eczema",
                    "Lebrikizumab",
                    "Meets Goal"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev",
            "features": {
                "keywords": [
                    "Insulet",
                    "Omnipod",
                    "FDA",
                    "Lyumjev"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",
            "features": {
                "keywords": [
                    "Lilly",
                    "Reorganizes",
                    "Neuroscience",
                    "Helius Medical",
                    "Breakthrough Designation",
                    "Ra Medical",
                    "Dermatology"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Eli Lilly creates neuroscience and immunology business units",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "neuroscience",
                    "immunology",
                    "business units"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly creates neuroscience and immunology business units",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units",
            "features": {
                "keywords": [
                    "Lilly",
                    "Leadership Changes",
                    "Neuroscience",
                    "Immunology",
                    "Business Units"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]